Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind comparison of tenofovir alafenamide vs tenofovir disoproxil fumarate in HBeAg-positive chronic hepatitis B
2013-000636-10Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Sep 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tenofovir alafenamide in Chronic Hepatitis B (CHB) (2 arms), sponsored by Gilead Sciences. Primary endpoint: HBV DNA suppression at week 48. Started Sep 2013; status: completed.
02
Drugs
tenofovir alafenamide
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2013-000636-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000636-10.